Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
RESEARCH TOOLSreports
Holding AMLX?
Track your performance easily
AMLX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.58 - $19.95
Previous Close$5.19
Volume831.82K
Average Volume (3M)1.44M
Market Cap
$355.76M
Enterprise Value$123.94M
Total Cash (Recent Filing)$234.40M
Total Debt (Recent Filing)$2.57M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Mar 26, 2025EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.82
Shares Outstanding68,547,860
10 Day Avg. Volume1,954,871
30 Day Avg. Volume1,442,428
Standard Deviation0.35
R-Squared0.01
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)1.83
Price to Sales (P/S)1.82
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.63
Enterprise Value/Gross Profit0.35
Enterprise Value/Ebitda-0.47
Forecast
1Y Price Target
$8.00Price Target Upside51.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Amylyx Pharmaceuticals Inc News
PremiumCompany Announcements
Amylyx Pharmaceuticals Q3 2024 Financial Highlights
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAvexitide, a GLP-1 receptor antagonist acquired by Amylyx, has shown promising Phase 2 results with a significant reduction in hypoglycemia events, indicating strong potential for future success.
Financial PerformanceAmylyx Pharmaceuticals has sufficient cash into 2026, ending 3Q25 with $234M in cash, providing financial stability for ongoing developments.
Market OpportunityAvexitide has the potential to become the first approved treatment for post-bariatric hypoglycemia (PBH), tapping into a growing market opportunity as the number of PBH patients is expected to rise over time.
Bears Say
Data ConcernsConcerns remain regarding the durability of effect and the robustness of the data due to the small sample size and open-label nature.
Pipeline UncertaintyAnalyst remains on the sidelines until additional clarity on the potential of the pipeline programs is obtained and reiterates a Market Perform rating.
Regulatory ChallengesThe company is on track to initiate the Phase 1 LUMINA study of AMX00114 in ALS in Canada, but this dose was not yet given the go-ahead by the FDA, which requested more information leading to a clinical hold in the US.
---
Ownership Overview
16.89% Insiders
8.82% Mutual Funds
28.70% Other Institutional Investors
38.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $1.57 and its highest was $19.95 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is Mar 26, 2025 which is in 123 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on Nov 07, 2024. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.704 by -$0.366.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc does not currently pay dividends.
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is -$0.56.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 68,547,860 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.704. Following the earnings report the stock price went up 5.145%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Among the largest hedge funds holding Amylyx Pharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds Amylyx Pharmaceuticals Inc’s shares valued at 7M.
---
Amylyx Pharmaceuticals Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (51.80% Upside)
$8.00 (51.80% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $243.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.93%
12-Months-Change
Fundamentals
Return on Equity
-84.43%
Trailing 12-Months
Asset Growth
-46.27%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
---
AMLX Earnings Call
Q3 2024
0:00 / 0:00
---
AMLX Stock 12 Month Forecast
Average Price Target
$8.00
▲(51.80% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Alnylam Pharma
―
Axsome Therapeutics
―
BioMarin Pharmaceutical
―
Best Analysts Covering AMLX
1 Year
1 Year Success Rate
7/18 ratings generated profit
1 Year Average Return
+5.97%
reiterated a buy rating 15 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 38.89% of your transactions generating a profit, with an average return of +5.97% per trade.
---